About
Probiodrug is a German biotechnology company developing therapeutics for Alzheimer’s disease by targeting formation of pyroglutamate-modified amyloid‑beta through inhibition of glutaminyl cyclase (lead program historically known as PQ912 / varoglutamstat).
Explore Probiodrug's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.